Dyskinesias Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study in Parkinson's Disease Patients With Moderate to Severe Dyskinesia to Assess the Efficacy and Safety/Tolerability of Two Dose Combinations of JM-010
The current study will explore the efficacy, safety and tolerability of 2 dose combinations of JM-010 to determine the optimal doses of each component to be studied in confirmatory clinical trials.
This is a Phase 2, double-blind, double-dummy, placebo-controlled, randomized, parallel group, multicentre study. Subjects with a diagnosis of moderate to severe dyskinesia in Parkinson's disease (PD) will complete a Screening Visit to assess eligibility to participate in the study. Subjects will continue with their usual levodopa treatment regimen for the duration of study participation. The screening assessment period will be a minimum of 1 week up to a maximum of 6 weeks. Subjects deemed to be eligible at the end of the Screening Visit will be randomly assigned in a 1:1:1 ratio to receive either 1 of the 2 dose combinations of JM-010 and 1 placebo, or 2 placebos as per the double-dummy study design. The randomized subjects will be followed treatment periods for 12 weeks and safety follow periods for 2 weeks, including pharmacokinetic (PK) sub-study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00986414 -
Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
|
Phase 2 | |
| Terminated |
NCT03270189 -
Effect of the Visual Information Change in Functional Dystonia
|
N/A | |
| Completed |
NCT05044572 -
Comparison of Open Chain Kinetic Exercises and Forward Head Posture Correction in Type II Scapular Dyskinesia
|
N/A | |
| Completed |
NCT01474421 -
Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
|
Phase 2 | |
| Suspended |
NCT04912115 -
Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia
|
Phase 2 | |
| Recruiting |
NCT05116813 -
Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy
|
Phase 2/Phase 3 | |
| Completed |
NCT01385592 -
Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
|
Phase 2 | |
| Completed |
NCT01491932 -
Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
|
Phase 2 | |
| Completed |
NCT00086294 -
ACP-103 to Treat Parkinson's Disease
|
Phase 2 | |
| Completed |
NCT00360568 -
Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects
|
Phase 3 | |
| Recruiting |
NCT05317390 -
Clinical Validation of DystoniaNet Deep Learning Platform for Diagnosis of Isolated Dystonia
|
N/A | |
| Active, not recruiting |
NCT04453995 -
A Follow-up of the Influencing Factors of Dyskinesia in Patients With Parkinson's Disease
|
||
| Not yet recruiting |
NCT05516875 -
Open-Label Extension Study of ASTORIA
|
Phase 2 | |
| Terminated |
NCT02589340 -
Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia
|
Phase 1 | |
| Completed |
NCT00076674 -
Levetiracetam Treatment of L-dopa Induced Dyskinesias
|
Phase 2 | |
| Completed |
NCT00888186 -
Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics
|
Phase 4 | |
| Completed |
NCT00004576 -
Study of LY300164 for the Treatment of Parkinson's Disease
|
Phase 2 | |
| Completed |
NCT00036296 -
Effects of Talampanel on Patients With Advanced Parkinson's Disease
|
Phase 1/Phase 2 | |
| Completed |
NCT00363727 -
Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's
|
Phase 3 | |
| Recruiting |
NCT04857359 -
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
|
Phase 2/Phase 3 |